Screener / SEC EDGAR /CIK 0000730272 /10-K filed Feb 26, 2026, compared with Mar 14, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Repligen Corp RGEN

Compare with peers Embed
What it said it expected, against what it reported

3 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 1 of 3 range targets
Below the range 0 below the last range given

The numbers RGEN said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Net income (company-defined)
Fiscal 2026
Given $109.00M to $114.00M release Feb 24, 2026
Raised $111.50M to $116.50M release May 5, 2026
Raised $115.50M to $118.50M release Jul 28, 2026
Raised $119.00M to $122.00M release Oct 27, 2026
– No standard number
The company's words
CURRENT GUIDANCE (at February 24, 2026) FY 2026 Adjusted (non-GAAP) … Net Income $109M - $114M release Feb 24, 2026
CURRENT GUIDANCE (at May 5, 2026) FY 2026 Adjusted (non-GAAP) … Net Income $111.5M - $116.5M release May 5, 2026
CURRENT GUIDANCE (at July 28, 2026) FY 2026 Adjusted (non-GAAP) … Net Income $115.5M - $118.5M release Jul 28, 2026
CURRENT GUIDANCE (at October 27, 2026) FY 2026 Adjusted (non-GAAP) … Net Income $119M - $122M release Oct 27, 2026
Diluted EPS (company-defined)
Fiscal 2026
Given $1.93 to $2.01 release Feb 24, 2026
Raised $1.97 to $2.05 release May 5, 2026
Raised $2.03 to $2.09 release Jul 28, 2026
Raised $2.05 to $2.09 release Oct 27, 2026
– No standard number
The company's words
CURRENT GUIDANCE (at February 24, 2026) FY 2026 Adjusted (non-GAAP) … Earnings Per Share - Diluted $1.93 - $2.01 release Feb 24, 2026
CURRENT GUIDANCE (at May 5, 2026) FY 2026 Adjusted (non-GAAP) … Earnings Per Share - Diluted $1.97 - $2.05 release May 5, 2026
CURRENT GUIDANCE (at July 28, 2026) FY 2026 Adjusted (non-GAAP) … Earnings Per Share - Diluted $2.03 - $2.09 release Jul 28, 2026
CURRENT GUIDANCE (at October 27, 2026) FY 2026 Adjusted (non-GAAP) … Earnings Per Share - Diluted $2.05 - $2.09 release Oct 27, 2026
Net income
Fiscal 2025 (ended Dec 31, 2025)
Given $51.00M to $56.00M release Feb 20, 2025
Lowered $43.00M to $48.00M release Apr 29, 2025
Raised $48.00M to $51.50M release Jul 29, 2025
Lowered $46.50M to $48.00M release Oct 28, 2025
$48.89M
10-K filed 2026-02-26
Above the range
The company's words
CURRENT GUIDANCE (at February 20, 2025) FY 2025 GAAP Adjusted (non-GAAP) … Net Income $51M - $56M release Feb 20, 2025
CURRENT GUIDANCE (at April 29, 2025) FY 2025 GAAP Adjusted (non-GAAP) … Net Income $43M - $48M release Apr 29, 2025
CURRENT GUIDANCE (at July 29, 2025) FY 2025 GAAP Adjusted (non-GAAP) … Net Income $48M - $51.5M release Jul 29, 2025
CURRENT GUIDANCE (at October 28, 2025) FY 2025 GAAP Adjusted (non-GAAP) … Net Income $46.5M - $48M release Oct 28, 2025
Diluted EPS
Fiscal 2025 (ended Dec 31, 2025)
Given $0.90 to $0.99 release Feb 20, 2025
Lowered $0.76 to $0.85 release Apr 29, 2025
Raised $0.85 to $0.92 release Jul 29, 2025
Lowered $0.82 to $0.85 release Oct 28, 2025
$0.86
10-K filed 2026-02-26
Above the range
The company's words
CURRENT GUIDANCE (at February 20, 2025) FY 2025 GAAP Adjusted (non-GAAP) … Earnings Per Share $0.90 - $0.99 release Feb 20, 2025
CURRENT GUIDANCE (at April 29, 2025) FY 2025 GAAP Adjusted (non-GAAP) … Earnings Per Share - Diluted $0.76 - $0.85 release Apr 29, 2025
CURRENT GUIDANCE (at July 29, 2025) FY 2025 GAAP Adjusted (non-GAAP) … Earnings Per Share - Diluted $0.85 - $0.92 release Jul 29, 2025
CURRENT GUIDANCE (at October 28, 2025) FY 2025 GAAP Adjusted (non-GAAP) … Earnings Per Share - Diluted $0.82 - $0.85 release Oct 28, 2025
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $630.00M to $639.00M release Nov 12, 2024
$634.44M
10-K filed 2025-03-14
Within the range
The company's words
Full year revenue guidance narrowed to range of $630-$639 million release Nov 12, 2024
2 targets far from the company's reported total, so not compared (usually a target for one product, segment or definition)
  • Net income, Fiscal 2024 (ended Dec 31, 2024): said $28.50M to $32.50M, reported -$25.51M. The company's words
  • Diluted EPS, Fiscal 2024 (ended Dec 31, 2024): said $0.51 to $0.58, reported $-0.46. The company's words

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2024-02-21), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGEN/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.